Overview

Omnitram Pharmacokinetic Study In Healthy Volunteers

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety, pharmacokinetic properties (the absorption, distribution and excretion), and analgesic activity of Omnitram (10 mg tablets), Tramadol (Ultram, 50 mg tablet) following oral administration of 9 doses healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Syntrix Biosystems, Inc.
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Tramadol